# US 12,109,183 B2 · Methods and compositions including protocatechuic acid crystals for the treatment of conditions caused by an enveloped virus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,109,183 B2
- Document ID: US12109183B2
- Status: Granted
- Kind: B2
- Application number: 17/453,432
- Filed: 2021-11-03
- Published: 2022-02-24
- Granted: 2024-10-08
- Earliest claimed: 2020-07-24
- Applicants: Lanny Leo Johnson
- Inventors: Lanny Leo Johnson
- Web page: https://patentgrep.com/patent/US12109183B2

## CPC

- A01N 37/40: having at least one carboxylic group or a thio analogue, or a derivative thereof, and one oxygen or sulfur atom attached to the same aromatic ring system
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A01P 1/00: Disinfectants; Antimicrobial compounds or mixtures thereof
- A61P 31/18: for HIV
- A61P 31/14: for RNA viruses
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A01P: BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

In embodiments, a method of treating a disease or condition caused by an enveloped virus in a mammal is disclosed including administering to the mammal a composition comprising protocatechuic acid crystals and disrupting the viral envelope of the enveloped virus. The mammal may be a human. The composition may include a pharmaceutically acceptable carrier. The enveloped virus may be a coronavirus. The enveloped virus may be a virus of the family Orthomyxoviridae.

## Claims

### Claim 1

A method of inactivating a human enveloped influenza virus type A: H1N1, H1N2, and H3N2; human enveloped influenza virus type B; or human enveloped influenza virus type C comprising:
orally administering to the human infected with human enveloped influenza virus type A: H1N1, H1N2, and H3N2; human enveloped influenza virus type B; or human enveloped influenza virus type C, a composition consisting of protocatechuic acid crystals; and
inactivating the enveloped virus.

### Claim 2 (depends on 1)

The method of claim 1, wherein the inactivating step comprises physical disruption of the viral envelope with the protocatechuic acid crystals, and the protocatechuic acid crystals further inactivate exposed RNA and/or DNA via its acidic pH of about 4.5.

### Claim 3 (depends on 1)

The method of claim 1, wherein the composition is in a capsule.

### Claim 4 (depends on 1)

The method of claim 1, wherein the oral administration dosage of the protocatechuic acid is a minimum of 500 to about 1000 milligrams per day.

### Claim 5 (depends on 1)

The method of claim 1, wherein the administration includes 50 mg/kg of the protocatechuic acid up to and at least every 6 hours for 4 days.